Saavi

Exothera announces industrial scale AAV manufacturing collaboration with LogicBio Therapeutics and Polyplus

Retrieved on: 
Wednesday, June 15, 2022
Solution, Industry, Therapy, GMP, Tissue, AAV, Vaccine, Technology, Transfection, Economics, Research, Saavi, Allegro, Single-use bioreactor, CDMO, DNA, Generides, Capsid, QC, Patient, Fine chemical

JUMET, Belgium, June 15, 2022 /PRNewswire/ -- Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L.

Key Points: 
  • JUMET, Belgium, June 15, 2022 /PRNewswire/ -- Exothera SAtoday announced a collaboration with LogicBio Therapeutics and Polyplus-transfection SA.
  • The collaboration among Exothera, LogicBio, and Polyplus aims to focus on the scale-up of a transient transfection-based AAV serotype 8 (AAV8) manufactured in suspension cell culture.
  • The success of AAV-based therapeutics requires a change in the manufacturing paradigm and through this collaboration, we aim to enable a new approach to consistently scale AAV manufacturing."
  • We believe our proprietary mAAVRx plasmid technology could dramatically help to improve manufacturing yields and consequently reduce AAV manufacturing costs.

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022
DNA, Therapy, AAV, Generides, Capsid, Transfection, Saavi, Investor, Tissue, Vaccine

LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer,Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conferencebeing heldMay 23-26, 2022.

Key Points: 
  • LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer,Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conferencebeing heldMay 23-26, 2022.
  • The pre-recorded presentation will be available for on-demand viewing beginning at7:00 a.m. ETonTuesday, May 24, 2022.
  • A webcast of the presentation will be made available on the Investors section of the company's website at https://investor.logicbio.com/ .
  • LogicBio Therapeuticsis a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

Retrieved on: 
Wednesday, May 11, 2022
Potent, Standard of care, Capsid, Design, Generides, AVV, HEK293, Alpha-fetoprotein, Nature, Cell, AAV, Gene, Hepatocellular carcinoma, Hepatocyte, Risk, Annual report, 2021 Essex County Council election, DNA, Tissue, Society, Transfection, Liver, U.S. Securities and Exchange Commission, SEC, Saavi, DOE, Annual general meeting, Therapy, Vaccine, Pharmaceutical industry

LEXINGTON, Mass., May 11, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts highlighting the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, held May 16-19, 2022, in Washington D.C. and virtually.

Key Points: 
  • LogicBio will present preclinical data from LB-401, its development candidate for the treatment of HT1.
  • The company believes that its optimized transfection process, which harnesses LogicBio's mAAVRx system, has the potential to significantly reduce per patient manufacturing costs.
  • LogicBio's downstream process improvements were made to accommodate the increased yield resulting from the company's optimized transfection process.
  • Securities and Exchange Commission(SEC) onMarch 4, 2022, and other filings that LogicBio may make with theSECin the future.

LogicBio Therapeutics to Present at Barclays Global Healthcare Conference

Retrieved on: 
Tuesday, March 8, 2022
DNA, AAV, Therapy, Tissue, Investor, Saavi, Generides, Conference, Company, Capsid, Vaccine

LEXINGTON, Mass., March 8, 2022 /PRNewswire/ -- LogicBioTherapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate in a fireside chat during the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m.

Key Points: 
  • LEXINGTON, Mass., March 8, 2022 /PRNewswire/ -- LogicBioTherapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate in a fireside chat during the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m.
  • A live webcast of the presentation will be made available on the Investors section of the Company's website at https://investor.logicbio.com .
  • LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.
  • The company's gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues.

Arix Bioscience PLC: Clinical development update from portfolio company LogicBio

Retrieved on: 
Wednesday, February 2, 2022
Growth, DNA, Risk, Patient, SAE, Therapy, Food, Investor, Șaeș, Patient safety, Clinical trial, Methylmalonic acidemia, Liver, Generides, List of life sciences, EMA, DSMB, Tissue, Data monitoring committee, Nasdaq, Saavi, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Homologous recombination, Hepatocyte, Cancer, Thrombotic microangiopathy, Program, Parenteral nutrition, European Medicines Agency, Company, Genome, Methylmalonyl-CoA mutase, Capsid, Time, Drug development, Survival, Industry, FDA, Association, Mouse, SUNRISE, AAV, TMA, Pharmaceutical industry, Vaccine, MMA, LB-001, LB-001

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

Key Points: 
  • Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
  • ET
    LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program.
  • The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA) has been placed on clinical hold.
  • The company will host a conference call and webcast this morning to discuss this update.

LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program

Retrieved on: 
Wednesday, February 2, 2022
Growth, Private Securities Litigation Reform Act, Safety, DNA, Risk, Patient, SAE, Therapy, U.S. Securities and Exchange Commission, Food, Investor, Șaeș, Clinical trial, Patient safety, Methylmalonic acidemia, Generides, Liver, EMA, DSMB, Tissue, Goal, Data monitoring committee, Patent, Saavi, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Homologous recombination, Hepatocyte, Cancer, Thrombotic microangiopathy, Program, Etto, Parenteral nutrition, Genome, Methylmalonyl-CoA mutase, Capsid, Time, Survival, FDA, Association, Mouse, SUNRISE, AAV, TMA, Pharmaceutical industry, Vaccine, MMA

LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program.

Key Points: 
  • LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program.
  • The FDA subsequently notified the company that the SUNRISE trial has been placed on clinical hold.
  • LogicBio will be working closely with the FDA and the DSMB to determine the next steps for the SUNRISE trial and the LB-001 program.
  • LogicBio will host a conference call and webcast today,Wednesday, February 2, 2022, at8:30 a.m. ETto discuss the program update.

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

Retrieved on: 
Tuesday, January 4, 2022
Generides, DNA, AAV, Investor, Saavi, Therapy, Company, Conference, Capsid, Tissue, Vaccine

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022.

Key Points: 
  • LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022.
  • The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m.
  • A webcast of the presentation will be made available on the Investors section of the Company's website at www.logicbio.com/investors .
  • LogicBio Therapeuticsis a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.

LogicBio Therapeutics Provides Business Updates

Retrieved on: 
Wednesday, December 22, 2021
Hepatocyte, Technology, Seizure, Disease, Tissue, Acquisition, Enzyme, COVID-19, Leadership, Generides, Brain, Clinical trial, Methylmalonyl-CoA, DNA, Patent, Methylmalonic acidemia, Risk, Patient, Vomiting, Genetic disorder, Bleeding, Board, Dartmouth, Acetone, Cancer, Nosebleed, Diarrhea, Hope, First Ever, Lethargy, AAV, Goal, Nervous system, Life, Genome, Time, Safety, SAE, Business, Shuttle Mission Simulator, Therapy, Brown University, Capsid, Mutation, Mouse, Profile, Homologous recombination, Tuck School of Business, Growth, FAH, Fats, Protein, Saavi, Board of directors, Survival, Jaundice, ESGCT, EMA, Liver, Lists of diseases, Bya, Research, FDA, Methylmalonyl-CoA mutase, Pharmaceutical industry, Vaccine, SUNRISE, MMA

LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.

Key Points: 
  • LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.
  • In accordance with its previously announced guidance, LogicBio alsoannounced the nomination of a new development candidate, LB-401, for the treatment of hereditary tyrosinemia type 1 (HT1).
  • in applied mathematics-economics from Brown University and an M.B.A. from the Tuck School of Business at Dartmouth.
  • "I am excited to join the LogicBio Board at what I believe is a pivotal time for the company," said Ms. Kahn.

LogicBio Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 11, 2021
Therapy, Tissue, Investor, Generides, Gene editing, Conference, Company, Capsid, London, DNA, Saavi, AAV, Pharmaceutical industry, Vaccine

LEXINGTON, Mass., Nov. 11, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc.(Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate at the following upcoming investor conferences:

Key Points: 
  • LEXINGTON, Mass., Nov. 11, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc.(Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate at the following upcoming investor conferences:
    Barclays Gene Editing & Gene Therapy Summit: Fireside chat at 8:00 a.m.
  • ET on Monday, November 15, 2021
    Jefferies Virtual London Healthcare Conference: Pre-recorded corporate presentation will be available beginning at 3:00 a.m.
  • LogicBio Therapeuticsis a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.
  • The company is based inLexington, MA.For more information, visit www.logicbio.com , which does not form a part of this release.

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children

Retrieved on: 
Monday, October 18, 2021
EMA, List of life sciences, AAV, Fats, Generides, Data monitoring committee, Genome, Industry, Liver, Time, Nasdaq, Methylmalonyl-CoA, Risk, Cancer, Growth, Mouse, Lethargy, Trial of the century, Capsid, European Medicines Agency, Protein, Tissue, Saavi, Methylmalonyl-CoA mutase, Brain, Mutation, FDA, Disease, DNA, Clinical trial, Patient, Survival, Food, Methylmalonic acidemia, DSMB, Seizure, Company, CRISPR, Drug development, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vomiting, SUNRISE, MD, Safety, Hepatocyte, Therapy, Homologous recombination, Lists of diseases, Pharmaceutical industry, Vaccine

www.arixbioscience.com

Key Points: 
  • www.arixbioscience.com
    - Based on safety data from first two patients, independent Data Safety Monitoring Board recommended continuation of trial, enabling enrollment of children as young as six months and dose escalation
    LEXINGTON, Mass., Oct. 18, 2021 -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children.
  • The SUNRISE trial is evaluating the safety, tolerability and preliminary efficacy of LB-001, the company's investigational, single-administration genome editing therapy, in pediatric patients with methylmalonic acidemia (MMA).
  • These results follow a recommendation from the independent Data Safety Monitoring Board (DSMB) overseeing the SUNRISE trial to continue the study without modification.
  • We look forward to continuing to progress the clinical study to better understand the biochemical and clinical effect of this genome editing therapy."